



**HAL**  
open science

# Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery

Mohamad Azhar Ajam Meerun

## ► To cite this version:

Mohamad Azhar Ajam Meerun. Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery. Human health and pathology. 2022. dumas-03925088

**HAL Id: dumas-03925088**

**<https://dumas.ccsd.cnrs.fr/dumas-03925088v1>**

Submitted on 14 Feb 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

UNIVERSITE DE MONTPELLIER  
FACULTE DE MEDECINE MONTPELLIER-NIMES

**THESE**

Pour obtenir le titre de  
**DOCTEUR EN MEDECINE**

Présentée et soutenue publiquement  
Par  
**Mohamad Azhar Ajam MEERUN**

le 21 Novembre 2022

TITRE

Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC)  
downstaged by Y90 using personalized dosimetry: safety, pathological results and  
outcomes after surgery

Directeur de thèse : Monsieur le Professeur Boris Guiu

JURY

Président : Monsieur le Professeur Boris Guiu

1<sup>er</sup> assesseur : Monsieur le Professeur Eric Assenat

2<sup>ème</sup> assesseur : Monsieur le Docteur Fabrizio Panaro

Membre invité : Madame le Docteur Carole Allimant

UNIVERSITE DE MONTPELLIER  
FACULTE DE MEDECINE MONTPELLIER-NIMES

**THESE**

Pour obtenir le titre de  
**DOCTEUR EN MEDECINE**

Présentée et soutenue publiquement  
Par  
**Mohamad Azhar Ajam MEERUN**

le 21 Novembre 2022

TITRE

Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC)  
downstaged by Y90 using personalized dosimetry: safety, pathological  
results and outcomes after surgery

Directeur de thèse : Monsieur le Professeur Boris Guiu

JURY

Président : Monsieur le Professeur Boris Guiu

1<sup>er</sup> assesseur : Monsieur le Professeur Eric Assenat

2<sup>ème</sup> assesseur : Monsieur le Docteur Fabrizio Panaro

Membre invité : Madame le Docteur Carole Allimant

**ANNEE UNIVERSITAIRE 2022-2023**  
**PERSONNEL ENSEIGNANT**

**Professeurs Honoraires**

ALBAT Bernard	BRUNEL Michel	HERTAULT Jean	NAVARRO Maurice
ALLIEU Yves	CAMU William	HUMEAU Claude	NAVRATIL Henri
ALRIC Robert	CANAUD Bernard	JAFFIOL Claude	OTHONIEL Jacques
ARNAUD Bernard	CHAPTAL Paul-André	JANBON Charles	PAGES Michel
ASENCIO Gérard	CIURANA Albert-Jean	JANBON François	PEGURET Claude
ASTRUC Jacques	CLOT Jacques	JARRY Daniel	PELISSIER Jacques
AUSSILLOUX Charles	COSTA Pierre	JOURDAN Jacques	PETIT Pierre
AVEROUS Michel	COTTALORDA Jérôme	KLEIN Bernard	POUGET Régis
AYRAL Guy	D'ATHIS Françoise	LAFFARGUE François	PUJOL Henri
BAILLAT Xavier	DEMAILLE Jacques	LALLEMANT Jean Gabriel	RABISCHONG Pierre
BALDET Pierre	DESCOMPS Bernard	LAMARQUE Jean-Louis	RAMUZ Michel
BALDY-MOULINIER Michel	DIMEGLIO Alain	LAPEYRIE Henri	REBOUL Jean
BALMES Jean-Louis	DUBOIS Jean Bernard	LEROUX Jean-Louis	RIEU Daniel
BANSARD Nicole	DUJOLS Pierre	LESBROS Daniel	ROCHFORT Henri
BILLIARD Michel	DUMAZER Romain	LOPEZ François Michel	ROUANET DE VIGNE LAVIT Jean Pierre
BLARD Jean-Marie	ECHENNE Bernard	LORiot Jean	SAINT-AUBERT Bernard
BLAYAC Jean Pierre	FABRE Serge	LOUBATIERES Marie Madeleine	SANCHO-GARNIER Héléne
BLOTMAN Francis	FREREBEAU Philippe	MAGNAN DE BORNIER Bernard	SANY Jacques
BONNEL François	GALIFER René Benoît	MARTY ANE Charles	SEGNARBIEUX François
BOURGEOIS Jean-Marie	GODLEWSKI Guilhem	MATHIEU-DAUDE Pierre	SENAC Jean-Paul
BOUSQUET Jean	GRASSET Daniel	MEYNADIER Jean	SERRE Arlette
BRUEL Jean Michel	GUILHOU Jean-Jacques	MICHEL François-Bernard	TOUITOU Isabelle
BUREAU Jean-Paul	GUITER Pierre	MION Charles	VIDAL Jacques
	HEDON berbard	MIRO Luis	VISIER Jean Pierre



**Professeurs Emérites**

**Docteurs Emerites**

ARTUS Jean-Claude	JONQUET Olivier	VOISIN Michel	PRAT Dominique
BASTIEN Patrick	LANDAIS Paul	ZANCA Michel	PUJOL Joseph
BLANC François	LARREY Dominique		
BONAFE Alain	LE QUELLEC Alain		
BOULENGER Jean-Philippe	MARES Pierre		
BOURREL Gérard	MAUDELONDE Thierry		
BRINGER Jacques	MAURY Michèle		
CLAUSTRES Mireille	MESSNER Patrick		
COMBE Bernard	MILLAT Bertrand		
DAURES Jean-Pierre	MONNIER Louis		
DAUZAT Michel	MOURAD Georges		
DAVY Jean-Marc	PREFAUT Christian		
DEDET Jean-Pierre	PUJOL Rémy		
DE LA COUSSAYE Jean-Emmanuel	RIBSTEIN Jean		
GROLLEAU RAOUX Robert	SCHVED Jean-François		
GUERRIER Bernard	SULTAN Charles		
GUILLOT Bernard	TOUCHON Jacques		
HERISSON Christian	UZIEL Alain		

**Professeurs des Universités - Praticiens Hospitaliers**

**PU-PH de classe exceptionnelle**

ALRIC Pierre	Chirurgie vasculaire ; médecine vasculaire (option chirurgie vasculaire)
BACCINO Eric	Médecine légale et droit de la santé
BEREGI Jean-Paul	Radiologie et imagerie médicale
BLAIN Hubert	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
BOULOT Pierre	Gynécologie-obstétrique ; gynécologie médicale
CANOVAS François	Anatomie
CAPDEVILA Xavier	Anesthésiologie-réanimation et médecine péri-opératoire
CHAMMAS Michel	Chirurgie orthopédique et traumatologique
COLSON Pascal	Anesthésiologie-réanimation et médecine péri-opératoire
COSTES Valérie	Anatomie et cytologie pathologiques
COUBES Philippe	Neurochirurgie
COURTET Philippe	Psychiatrie d'adultes ; addictologie
CRAMPETTE Louis	Oto-rhino-laryngologie
CRISTOL Jean Paul	Biochimie et biologie moléculaire
CYTEVAL Catherine	Radiologie et imagerie médicale
DE WAZIERES Benoît	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
DELAPORTE Eric	Maladies infectieuses ; maladies tropicales
DEMOLY Pascal	Pneumologie ; addictologie
DOMERGUE Jacques	Chirurgie viscérale et digestive
DUFFAU Hugues	Neurochirurgie
ELIAOU Jean François	Immunologie
FABRE Jean Michel	Chirurgie viscérale et digestive
HAMAMAH Samir	Biologie et Médecine du développement et de la reproduction ; gynécologie médicale
JABER Samir	Anesthésiologie-réanimation et médecine péri-opératoire
JEANDEL Claude	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
JORGENSEN Christian	Thérapeutique ; médecine d'urgence ; addictologie
KOENIG Michel	Génétique
KOTZKI Pierre Olivier	Biophysique et médecine nucléaire
LABAUGE Pierre	Neurologie
LAFFONT Isabelle	Médecine physique et de réadaptation

LEFRANT Jean-Yves	Anesthésiologie-réanimation et médecine péri-opératoire
LEHMANN Sylvain	Biochimie et biologie moléculaire
LUMBROSO Serge	Biochimie et Biologie moléculaire
MARIANO-GOULART Denis	Biophysique et médecine nucléaire
MERCIER Jacques	Physiologie
MEUNIER Laurent	Dermato-vénéréologie
MONDAIN Michel	Oto-rhino-laryngologie
MORIN Denis	Pédiatrie
PAGEAUX Georges-Philippe	Gastroentérologie ; hépatologie ; addictologie
PUJOL Pascal	Biologie cellulaire
QUERE Isabelle	Chirurgie vasculaire ; médecine vasculaire (option médecine vasculaire)
RENARD Eric	Endocrinologie, diabète et maladies métaboliques ; gynécologie médicale
REYNES Jacques	Maladies infectieuses, maladies tropicales
RIPART Jacques	Anesthésiologie-réanimation et médecine péri-opératoire
ROUANET Philippe	Cancérologie ; radiothérapie
SOTTO Albert	Maladies infectieuses ; maladies tropicales
TAOUREL Patrice	Radiologie et imagerie médicale
VANDE PERRE Philippe	Bactériologie-virologie ; hygiène hospitalière
VERNHET Hélène	Radiologie et imagerie médicale
YCHOU Marc	Cancérologie ; radiothérapie

#### **PU-PH de 1<sup>re</sup> classe**

AGUILAR MARTINEZ Patricia	Hématologie ; transfusion
ASSENAT Éric	Gastroentérologie ; hépatologie ; addictologie
AVIGNON Antoine	Nutrition
AZRIA David	Cancérologie ; radiothérapie
BAGHDADLI Amaria	Pédopsychiatrie ; addictologie
BLANC Pierre	Gastroentérologie ; hépatologie ; addictologie
BORIE Frédéric	Chirurgie viscérale et digestive
BOURDIN Arnaud	Pneumologie ; addictologie
CAMBONIE Gilles	Pédiatrie
CAPTIER Guillaume	Anatomie

CARTRON Guillaume	Hématologie ; transfusion
CAYLA Guillaume	Cardiologie
CHANQUES Gérard	Anesthésiologie-réanimation et médecine péri-opératoire
CORBEAU Pierre	Immunologie
COULET Bertrand	Chirurgie orthopédique et traumatologique
CUVILLON Philippe	Anesthésiologie-réanimation et médecine péri-opératoire
DADURE Christophe	Anesthésiologie-réanimation et médecine péri-opératoire
DAUVILLIERS Yves	Physiologie
DE TAYRAC Renaud	Gynécologie-obstétrique, gynécologie médicale
DE VOS John	Histologie, embryologie et cytogénétique
DEMARIA Roland	Chirurgie thoracique et cardio-vasculaire
DEREURE Olivier	Dermatologie - vénéréologie
DROUPY Stéphane	Urologie
DUCROS Anne	Neurologie
DUPEYRON Arnaud	Médecine physique et de réadaptation
FESLER Pierre	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
GARREL Renaud	Oto-rhino-laryngologie
GENEVIEVE David	Génétique
GUILLAUME Sébastien	Psychiatrie d'adultes ; addictologie
GUIU Boris	Radiologie et imagerie médicale
HAYOT Maurice	Physiologie
HOUEDE Nadine	Cancérologie ; radiothérapie
JUNG Boris	Médecine intensive-réanimation
KALFA Nicolas	Chirurgie infantile
KLOUCHE Kada	Médecine intensive-réanimation
KOUYOUMDJIAN Pascal	Chirurgie orthopédique et traumatologique
LACHAUD Laurence	Parasitologie et mycologie
LAVABRE-BERTRAND Thierry	Histologie, embryologie et cytogénétique
LAVIGNE Jean-Philippe	Bactériologie-virologie ; hygiène hospitalière
LE MOING Vincent	Maladies infectieuses ; maladies tropicales
LECLERCQ Florence	Cardiologie
MATECKI Stéfan	Physiologie

MORANNE Olivier	Néphrologie
MOREL Jacques	Rhumatologie
NAVARRO Francis	Chirurgie viscérale et digestive
NOCCA David	Chirurgie viscérale et digestive
PANARO Fabrizio	Chirurgie viscérale et digestive
PASQUIE Jean-Luc	Cardiologie
PEREZ MARTIN Antonia	Chirurgie vasculaire ; médecine vasculaire (option médecine vasculaire)
PERNEY Pascal	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
PRUDHOMME Michel	Anatomie
PUJOL Jean Louis	Pneumologie ; addictologie
PURPER-OUAKIL Diane	Pédopsychiatrie ; addictologie
ROGER Pascal	Anatomie et cytologie pathologiques
TRAN Tu-Anh	Pédiatrie

**PU-PH de 2ème classe**

AYRIGNAC Xavier	Neurologie
BELZEAUX Raoul	Psychiatrie d'adultes ; Addictologie
BERTRAND Martin	Anatomie
BOBBIA Xavier	Médecine d'urgence
BOURGIER Céline	Cancérologie ; radiothérapie
CANAUD Ludovic	Chirurgie vasculaire ; médecine vasculaire (option chirurgie vasculaire)
CAPDEVIELLE Delphine	Psychiatrie d'Adultes ; addictologie
CLARET Pierre-Géraud	Médecine d'urgence
COLOMBO Pierre-Emmanuel	Cancérologie ; radiothérapie
COSTALAT Vincent	Radiologie et imagerie médicale
DAIEN Vincent	Ophthalmologie
DE JONG Audrey	Anesthésiologie-réanimation et médecine péri-opératoire
DONNADIEU Hélène	Gastroentérologie ; hépatologie ; addictologie
DORANDEU Anne	Médecine légale et droit de la santé
FAILLIE Jean-Luc	Pharmacologie fondamentale ; pharmacologie clinique ; addictologie
FRANDON Julien	Radiologie et imagerie médicale
FUCHS Florent	Gynécologie-obstétrique ; gynécologie médicale
GABELLE DELOUSTAL Audrey	Neurologie

GANDET Thomas	Chirurgie thoracique et cardiovasculaire
GAUJOUX Viala Cécile	Rhumatologie
GELIS Anthony	Médecine physique et de réadaptation
GODREUIL Sylvain	Bactériologie-virologie ; hygiène hospitalière
GUILPAIN Philippe	Médecine Interne, gériatrie et biologie du vieillissement; addictologie
HERLIN Christian	Chirurgie plastique, reconstructrice et esthétique, brulologie
IMMEDIATO DAIEN Claire	Rhumatologie
JACOT William	Cancérologie ; Radiothérapie
JEZIORSKI Eric	Pédiatrie
LALLEMANT Benjamin	Oto-rhino-laryngologie
LATTUCA Benoît	Cardiologie
LE QUINTREC DONNETTE Moglie	Néphrologie
LETOUZEY Vincent	Gynécologie-obstétrique ; gynécologie médicale
LONJON Nicolas	Neurochirurgie
LOPEZ CASTROMAN Jorge	Psychiatrie d'Adultes ; addictologie
LUKAS Cédric	Rhumatologie
MAKINSON Alain	Maladies infectieuses, Maladies tropicales
MENJOT de CHAMPFLEUR Nicolas	Radiologie et imagerie médicale
MILLET Ingrid	Radiologie et imagerie médicale
MURA Thibault	Biostatistiques, informatique médicale et technologies de la communication
NAGOT Nicolas	Biostatistiques, informatique médicale et technologies de la communication
OLIE Emilie	Psychiatrie d'adultes; addictologie
PARIS Françoise	Biologie et médecine du développement et de la reproduction ; gynécologie médicale
PELLESTOR Franck	Histologie, embryologie et cytogénétique
PERS Yves-Marie	Thérapeutique; addictologie
POUDEROUX Philippe	Gastroentérologie ; hépatologie ; addictologie
RIGAU Valérie	Anatomie et cytologie pathologiques
RIVIER François	Pédiatrie
ROGER Claire	Anesthésiologie-réanimation et médecine péri-opératoire
ROSSI Jean François	Hématologie ; transfusion
ROUBILLE François	Cardiologie
SEBBANE Mustapha	Médecine d'urgence



SIRVENT Nicolas	Pédiatrie
SOLASSOL Jérôme	Biologie cellulaire
STERKERS Yvon	Parasitologie et mycologie
STOEBNER Pierre	Dermato-vénérologie
SULTAN Ariane	Nutrition
THOUVENOT Éric	Neurologie
THURET Rodolphe	Urologie
TUAILLON Edouard	Bactériologie-virologie; hygiène hospitalière
VENAIL Frédéric	Oto-rhino-laryngologie
VILLAIN Max	Ophtalmologie
VINCENT Denis	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
VINCENT Thierry	Immunologie

#### PROFESSEURS DES UNIVERSITES

##### 1<sup>re</sup> classe :

COLINGE Jacques (Cancérologie, Signalisation cellulaire et systèmes complexes)

LAOUDJ CHENIVESSE Dalila (Biochimie et biologie moléculaire)

VISIER Laurent (Sociologie, démographie)

##### 2<sup>ème</sup> classe :

HAZAL Nathalie (Biologie cellulaire)

MOREAUX Jérôme (Sciences biologiques fondamentales et cliniques)

#### PROFESSEURS DES UNIVERSITES - Médecine générale

##### 1<sup>re</sup> classe :

AMOUYAL Michel

#### PROFESSEURS ASSOCIES - Médecine Générale

CLARY Bernard

GARCIA Marc

MILLION Elodie

REBOUL Marie-Catherine

#### PROFESSEURS ASSOCIES - Médecine

BESSIS Didier (Dermato-vénérologie)

DEBIEN Blaise (Médecine d'urgence)

MEUNIER Isabelle (Ophtalmologie)

MULLER Laurent (Anesthésiologie-réanimation et médecine péri-opératoire)

PERRIGAULT Pierre-François (Anesthésiologie-réanimation et médecine péri-opératoire)

QUANTIN Xavier (Pneumologie)

ROUBERTIE Agathe (Pédiatrie)

VIEL Eric (Soins palliatifs et traitement de la douleur)

### **Maîtres de Conférences des Universités - Praticiens Hospitaliers**

#### **MCU-PH Hors classe - Echelon Exceptionnel**

MARTRILLE Laurent Médecine légale et droit de la santé

RICHARD Bruno Médecine palliative

#### **MCU-PH Hors classe**

BADIOU Stéphanie Biochimie et biologie moléculaire

BOULLE Nathalie Biologie cellulaire

CACHEUX-RATABOUL Valère Génétique

CARRIERE Christian Bactériologie-virologie ; hygiène hospitalière

CHARACHON Sylvie Bactériologie-virologie ; hygiène hospitalière

FABBRO-PERAY Pascale Epidémiologie, économie de la santé et prévention

GIANSILY-BLAIZOT Muriel Hématologie ; transfusion

#### **MCU-PH de 1<sup>re</sup> classe**

BOUDOUSQ Vincent Biophysique et médecine nucléaire

BRET Caroline Hématologie biologique

BROUILLET Sophie Biologie et médecine du développement et de la reproduction ; gynécologie médicale

COSSEE Mireille Génétique

GIRARDET-BESSIS Anne Biochimie et biologie moléculaire

HERRERO Astrid Chirurgie viscérale et digestive

LAVIGNE Géraldine Hématologie ; transfusion

LESAGE François-Xavier Médecine et Santé au Travail

MATHIEU Olivier Pharmacologie fondamentale ; pharmacologie clinique ; addictologie

MOUZAT Kévin Biochimie et biologie moléculaire

PANABIÈRES Catherine Biologie cellulaire

RAVEL Christophe Parasitologie et mycologie

SCHUSTER-BECK Iris	Physiologie
THEVENIN-RENE Céline	Immunologie

**MCU-PH de 2<sup>ème</sup> classe**

BARATEAU Lucie	Physiologie
BERGOUIGNOUX Anne	Génétique
BOETTO Julien	Neurochirurgie
CHIRIAC Anca	Immunologie
DESHAYES Emmanuel	Biophysique et médecine nucléaire
DUFLOS Claire	Biostatistiques, informatique médicale et technologies de la communication
DU THANH Aurélie	Dermato-vénérologie
ENGELMANN Ilka	Bactériologie-virologie ; hygiène hospitalière
FITENI Frédéric	Cancérologie ; radiothérapie
GATINOIS Vincent	Histologie, embryologie et cytogénétique
GOUZI Farès	Physiologie
HERBAUX Charles	Hématologie, transfusion
HUBERLANT Stéphanie	Gynécologie-obstétrique ; Gynécologie médicale
LEVEQUE Maude	Parasitologie et mycologie
MARIA Alexandre	Médecine interne ; gériatrie et biologie du vieillissement ; addictologie
PANTEL Alix	Bactériologie-virologie ; hygiène hospitalière
RANISAVELJEVIC Noémie	Biologie et médecine du développement et de la reproduction ; Gynécologie médicale
ROUBILLE Camille	Médecine interne ; gériatrie et biologie du vieillissement ; addictologie
SOUICHE François-Régis	Chirurgie viscérale et digestive
SZABLEWSKY	Anatomie et cytologie pathologiques

**Maitres de Conférences des Universités**

**Maitres de Conférences hors classe**

BECAMEL Carine	Neurosciences
DELABY Constance	Biochimie et biologie moléculaire
MAIMOUN Laurent	Sciences physico-chimiques et ingénierie appliquée à la santé

**Maîtres de Conférences de classe normale**

CHAUMONT-DUBEL Séverine	Sciences du médicament et des autres produits de santé
GUGLIELMI Laurence	Sciences biologiques fondamentales et cliniques
HENRY Laurent	Sciences biologiques fondamentales et cliniques
HERBET Guillaume	Neurosciences
HERVE ANDRE Emilie	
LADRET Véronique	Mathématiques appliquées et applications des mathématiques
LAINE Sébastien	Sciences du Médicament et autres produits de santé
LE GALLIC Lionel	Sciences du médicament et autres produits de santé
LOZZA Catherine	Sciences physico-chimiques et technologies pharmaceutiques
MORITZ-GASSER Sylvie	Neurosciences
MOUTOT Gilles	Philosophie
PASSERIEUX Emilie	Physiologie
RAMIREZ Jean-Marie	Histologie
RAYNAUD Fabrice	Sciences du Médicament et autres produits de santé
TAULAN Magali	Biologie Cellulaire

**Maîtres de Conférences des Universités - Médecine Générale**

**MCU-MG de 1<sup>er</sup> classe**

COSTA David  
OUDE ENGBERINK Agnès

**MCU-MG de 2<sup>ème</sup> classe**

FOLCO-LOGNOS Béatrice  
CARBONNEL François

**Maîtres de Conférences associés - Médecine Générale**

BADIN Mélanie  
CAMPAGNAC Jérôme  
LOPEZ Antonio  
MINET Mathilde  
PAVAGEAU Sylvain  
SERAYET Philippe

### Praticiens Hospitaliers Universitaires

CAZAUBON Yoann	Pharmacologie fondamentale ; pharmacologie clinique ; addictologie
DAGNEAUX Louis	Chirurgie orthopédique et traumatologique
GAVOTTO Arthur	Pédiatrie
GOULABCHAND Radjiv	Médecine interne ; gériatrie et biologie du vieillissement ; addictologie
MIOT Stéphanie	Médecine interne ; gériatrie et biologie du vieillissement ; addictologie
POULEN Gaetan	Neurochirurgie
ROCH Benoît	Pneumologie, addictologie
URSIC BEDOYA José	Gastroentérologie ; hépatologie ; addictologie

**PH chargés d'enseignements**

ABOUKRAT Patrick	BRISOT Dominique	FAURE Elsa	MARTIN Lucille	SEGURET Fabienne
AGUILHON Sylvain	BRONER Jonathan	FILLERON Anne	MATTATIA Laurent	SENESSE Pierre
AKKARI Mohamed	CAIMMI Davide Paolo	FILLOLS Mélanie	MEROUEH Fadi	SERRE Jean-Emmanuel
ALRIC Jérôme	CARR Julie	FOURNIER Philippe	MEYER Pierre	SKALLI EI Medhi
AMEDRO Pascal	CARTIER César	GAILLARD Nicolas	MICHEL Moïse	SOLA Christelle
AMOUROUX Cyril	CASPER Thierry	GALMICHE Sophie	MILESI Christophe	SOULLIER Camille
ANTOINE Valéry	CASSINOTTO Christophe	GENY Christian	MORAU Estelle	SOUKSI MEDIONI Isabelle
ARQUIZAN Caroline	CATHALA Philippe	GERONIMI Laetitia	MORQUIN David	STOEBNER DELBARRE Anne
ATTALIN Vincent	CAZABAN Michel	GINIES Patrick	MOSER Camille	TEOT Luc
BADR Maliha	CHARBIT Jonathan	GRECO Frédéric	MOUSTY Eve	THIRION Marina
BAIS Céline	CHEVALLIER Thierry	GROSSIN Delphine	MOUTERDE Gaël	TUNEZ Virginie
BARBAR Saber Davide	CHEVALLIER-MICHAUD Jo	GUEDJ Anne Marie	PERNIN Vincent	VACHIERY-LAHAYE Florence
BASSET Didier	COLIN Olivier	GUYON Gaël	PERRIGAULT Pierre François	VERNES Eric
BATIFOL Dominique	CONEJERO Ismael	HEDON Christophe	PEYRON Pierre-Antoine	VIALA Maurice
BATTISTELLA Pascal	CONSEIL Mathieu	HENRY Vincent	PICARD Eric	VINCENT Laure
BAUCHET Luc	CORBEAU Catherine	JAMMET Patrick	PICOT Marie Christine	WAGNER Laurent
BELL Ariane	COROIAN Flavia-Oana	JEDRYKA François	POQUET Hélène	WALTHER LOUVIER Ulrike
BENEZECH Jean-Pierre	COUDRAY Sarah	JREIGE Riad	PUJOL Sarah-Lise	ZERKOWSKI Laetitia
BENNYNS Karim	CUNTZ Danielle	KINNE Mélanie	PUPIER Florence	
BERNARD Nathalie	DARDALHON Brigitte	LABARIAS Coralie	QUANTIN Xavier	
BERTCHANSKY Ivan	DAVID Aurore	LABORDE Caroline	RAFFARD Laurence	
BIBOULET Philippe	DE BOUTRAY Marie	LACAMBRE Mathieu	RAPIDO Francesca	
BIRON-ANDREANI Christine	DE LA TRIBONNIÈRE Xavie	LANG Philippe	RIBRAULT Alice	
BLANC Brigitte	DEBIEN Blaise	LAZERGES Cyril	RICHAUD-MOREL Brigitte	
BLANCHARD Sylvie	DELPONT Marion	LE GUILLOU Cédric	RIDOLFO Jérôme	
BLANCHET Catherine	DENIS Hélène	LEGLISE Marie Suzanne	RIPART Sylvie	
BLATIERE Véronique	DEVILLE de PERIERE Gilles	LE MOINE DONY Marie-Christine	RONGIERES Michel	
BOGE Gudrun	DI CASTRI Alberto	LETERTRE Simon	ROULET Agnès	
BOURRAIN Jean Luc	DJANIKIAN Flora	LOPEZ Régis	RUBENOVITCH Josh	
BOUYABRINE Hassan	FAIDHERBE Jacques	LUQUIENS Amandine	SANTONI Fannie	
BRINGER-DEUTSCH Sophie	FATTON Brigitte	MANZANERA Cyril	SASSO Milène	
BRINGUIER BRANCHEREAU Sophie	FAUCHERRE Vincent	MARGUERITTE Emmanuel	SCHULDINER Sophie	

## REMERCIEMENTS

### **Aux membres de mon Jury**

Au Pr Boris Guiu, de m'offrir l'opportunité de travailler avec votre équipe. Faire de la recherche à vos côtés est une immense honneur. Merci pour vos encouragements, votre écoute et votre disponibilité . Votre détermination à faire avancer la science pour améliorer la santé des patients est un exemple à suivre.

Au Pr Eric Assenat, d'avoir accepté d'être membre de mon jury et d'apporter votre expertise oncologique.

Au Docteur Fabrizio Panaro, d'avoir accepté d'être membre de mon jury et d'apporter votre expertise en chirurgie digestive.

A Docteur Carole Allimant, de m'avoir accompagné pendant toute la phase de recueil de données et d'écriture de la thèse. Merci pour tes idées brillantes qui non seulement ont donné jour à ce travail mais qui bénéficieront à de nombreux patients.

### **A l'équipe de Saint Eloi,**

A Marie-Ange Pierredon-Foulongne, Valentina Scembri, Ali Belgour, Christophe Cassinotto, Lauranne, Julie Lonjon, Margaux Hermida, Bachir Benoudifa et Laure Escal. Vous m'avez initié à la radiologie diagnostique et interventionnelle lors de mon passage chez vous en premier semestre. Votre rigueur, votre maîtrise de la radiologie oncologique et votre investissement dans le service est, pour moi, un exemple à suivre.

A Ancelin, Philippe, Héloïse, Nicolas et Anthony, mes premier co-internes. Merci pour votre entraide et votre bonne humeur pendant tout le stage.

### **A l'équipe de Beau Soleil,**

A Muriel Viala-Trentini, Julie Bolivar, Julie Colleau, Benjamin Langman, Florian Danière et Silvia Gaudin pour l'initiation à l'imagerie pelvienne, l'ostéoarticulaire, la neuroradiologie.

A Quentin Filias pour l'entraide et la bonne humeur pendant tout le stage

### **A l'équipe de Gui de Chauliac,**

Au professeur Vincent Costalat, au professeur Nicolas Menjot, Cyril Dargazanli, Imad Derraz, Arthur Coget, Pierre-Henri Lefevre, Gregory Gasco, Federico Cagnazzo, Carlos Riquelme pour toutes les connaissances indispensables qu'ils m'ont transmises en neuroradiologie diagnostique et interventionnelle

A Nicolas Lebouq pour toutes les précieuses connaissances qu'il m'a transmis en neuroradiologie pédiatrique notamment par son investissement et expertise au staff de pédiatrie

A Mehdi Mahmoudi, Mathilde Carrière et Eve Denis. Au-delà des innombrables connaissances que vous m'avez apportées, je vous remercie pour votre disponibilité, votre écoute et votre accompagnement pendant tout le semestre.

A Marine Dumon, Godchaux Laurie-Anne, Diviez Julien, Philippe Lam, Carole Chevalier, Julie Piarroux pour l'entraide et la bonne humeur pendant tout le stage.

#### **A l'équipe d'Arnaud De Villeneuve,**

Au Professeur Kovacsik Helene, Bommart Sebastien, Zarqane Hamid, Vanoverschelde Juliette, Valérie Monnin-bares, Benoit Azaïs pour toutes les précieuses connaissances qu'ils m'ont transmis en imagerie cardio-thoracique et en radiologie interventionnelle.

A Réjane Martin, Renaud Sales, Fabien De Oliveira pour l'entraide et la bonne humeur pendant tout le stage.

#### **A l'équipe de Lapeyronnie,**

Aux professeurs Catherine Cyteval, Yann Thouvenin, Marie-Pierre Baron-Sarrabère pour toutes les précieuses connaissances qu'ils m'ont transmis en ostéoarticulaire et en radiologie interventionnelle. Merci pour tous les précieux conseils pour l'avenir et de m'avoir donné l'occasion de réaliser des gestes en radiologie interventionnelle.

Au professeur Ingrid Millet, pour son écoute, sa disponibilité, sa bonne humeur et ses astuces en imagerie diagnostique des urgences, en imagerie de la femme et en imagerie digestive. Vous êtes en exemple à suivre.

Au professeur Patrice Taourel, Caroline Mandoul, Juliette Coutureau, Emma Pages-Bouic, Cécile Verheyden et Fernanda Curos pour tous les précieux conseils pour l'avenir et pour toutes les précieuses connaissances en imagerie de la femme. Merci pour la bonne ambiance que vous entretenez au travail qui est un exemple à suivre.

A Delebecq Jessica, Benjamin Monsonis, Nadia Ouzzin, Arthur Hamel-Senecal, William Wantz, Ugo Chamard-Champlaud pour les innombrables connaissances que vous m'avez apportées et je vous remercie pour votre disponibilité, votre écoute et votre accompagnement pendant tout le semestre.

A Adamfa Coulibaly et à Morgane Lanouzière pour les bons moments pendant le stage, à la SIFEM et pour vos précieux conseils, votre bonne humeur et votre complicité

A Maxime Pastor, Paul Segui, Thorgal Brun, Judith Legrand et à Tom Paunet pour l'entraide et la bonne humeur pendant tout le stage.

Aux autres coninternes que j'ai croisés pendant mes stages

A mes camarades de promotion, Louis Carmier, Jules Galerne, Chakir Hocine, Agathe Debeauvais pour l'entraide et la bonne humeur

Aux manipulateurs, aux infirmières et autres paramédicaux sans qui exercer le travail de radiologue serait impossible.

### **A ma famille**

Papa, Maman et Asif, sans qui je ne serai pas en France aujourd'hui pour leur écoute et leurs encouragements incommensurables

Nuz pour son soutien et ses conseils

A Rémi, qui m'encourage à être la meilleure version de moi-même et pour son soutien infailible

A la famille Richard (Géra, Sylvain, Lu, les tontons, Monique, Olive et Olivia)

A Shal et Koum

A Amandine, Méja, Atish, Kyan, Romain, Meena

## SOMMAIRE

<b>RESUME en français</b>	<b>p.20</b>
<b>ABSTRACT, résumé en anglais</b>	<b>p.21</b>
<b>INTRODUCTION</b>	<b>p.22-23</b>
<b>ARTICLE</b>	
<b>ABSTRACT, résumé</b>	<b>p.24</b>
<b>INTRODUCTION, METHODS, introduction, méthodes</b>	<b>p.25-27</b>
<b>RESULTS, résultats</b>	<b>p.27-33</b>
<b>DISCUSSION, discussion</b>	<b>p.34-36</b>
<b>REFERENCES, bibliographie</b>	<b>p.36-38</b>
<b>SUPPLEMENTARY DATA, données supplémentaires</b>	<b>p.39-40</b>
<b>SERMENT</b>	<b>p.41</b>

# **Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery.**

## **RÉSUMÉ**

### **Contexte**

La radio-embolisation (RE) a récemment été reconnue comme un traitement d'accompagnement à la chirurgie pour les carcinomes hépatocellulaires (CHC) précoces avec des taux élevés de nécrose histologique complète (NHC). Chez les patients avec un thrombus tumoral de la veine porte (TTVP), des tumeurs multifocales ou de grandes tailles, la RE a principalement un rôle palliatif et la chirurgie reste discutable.

### **Méthodes**

Dans cette étude rétrospective, nous avons évalué la tolérance, la réponse radiologique, la réponse histologique et la survie des patients atteints de CHC avec des TTVP, des tumeurs multifocales ou de grande taille, opérés après RE avec une dosimétrie personnalisée.

### **Résultats**

Entre décembre 2015 et octobre 2021, dix-huit patients (14/18 avec TTVP) ont été opérés après RE. Aucune mortalité à 90 jours n'a été rapportée. Le taux de réponse objective radiologique était de 95 %. Une NHC et une nécrose histologique étendue (50-99%) ont été observées respectivement dans 36% et 45% des tumeurs. La dose absorbée par la tumeur après RE différait significativement selon l'étendue de la nécrose histologique ( $P=0,045$ ). Les médianes de survie globale et sans progression étaient respectivement de 61,8 mois [IC 95 % : 31,4 mois-non atteint (NA)] et 49,3 mois (IC 95 % : 14 mois-NA).

### **Conclusions**

Des taux élevés de réponses radiologiques et histologiques ont été observés après RE chez les patients atteints de TTVP, de CHC de grande taille ou multifocaux. La chirurgie ultérieure est sûre avec des résultats dépassant de loin les attentes dans une population au pronostic autrement défavorable.

### **Spécialité**

Radiologie interventionnelle ; Hépatologie ; Chirurgie ; Médecine nucléaire

### **Mots clés**

Radiothérapie interne sélective ; carcinome hépatocellulaire (CHC) ; cancer du foie ; résection ; transplantation.

# **Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery.**

## **ABSTRACT**

### **Background**

Transarterial radioembolization (TARE) has recently been recognized as a bridging/downstaging therapy to surgery for early hepatocellular carcinomas (HCCs) with high rates of complete pathological necrosis (CPN). In patients with portal vein tumoral thrombus (PVTT), multifocal or large tumors, TARE has mainly a palliative role and surgery remains controversial. Personalized dosimetry recently proved to outperform standard dosimetry.

### **Methods**

In this retrospective study, we evaluated safety, radiological and pathological response and outcomes in HCC patients with PVTT, multifocal or large tumors, who underwent surgery after downstaging using TARE with personalized dosimetry.

### **Results**

Between December 2015 and October 2021, eighteen unresectable patients (14/18 with PVTT) had surgery 6.2 months (range, 2–14.6 months) after a single Y90 treatment. No 90-day mortality was reported. Objective modified response criteria in solid tumors (mRECIST) response rate was 95%. Complete and extensive (50–99%) necrosis was observed in 36% and 45% of tumors, respectively. The post-treatment tumor-absorbed dose significantly differed depending on the extent of pathological necrosis ( $P=0.045$ ). Median overall survival and progression-free survival (PFS) were respectively of 61.8 months [95% CI: 31.4 months–not reached (NR)] and 49.3 months (95% CI: 14 months–NR). PFS was longer in patients with complete imaging response and in those with CPN.

### **Conclusions**

Y90 TARE using personalized dosimetry can provide high rates of imaging and pathological response in patients with PVTT, large or multifocal HCC. Subsequent surgery is safe and leads to outcomes far exceeding expectations in an otherwise poor prognosis population with no chance for cure.

### **Specialty**

Interventional radiology; Hepatology; Surgery; Nuclear medicine

### **Keywords**

Selective internal radiation therapy; hepatocellular carcinoma (HCC); liver cancer; resection; transplantation

## **Large, multifocal or portal vein-invading HCCs downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery**

### **INTRODUCTION**

La radioembolisation (RE) a récemment été ajoutée dans les recommandations du BCLC (1), suite aux résultats de l'étude LEGACY. Cette étude rapporte des résultats comparables après RE à ceux obtenus après des traitements à visée curative des carcinome hépatocellulaires (CHC) uniques de  $\leq 8$ cm (2). La RE était également soutenue par le taux élevé de réponse histologique complète dans cette population (3-5). En revanche, la place de la RE dans les CHC BCLC B/C et, plus spécifiquement, dans les CHC de grande taille ( $> 8$ cm), multifocaux ou avec thrombus tumoral de la veine porte (TTVP) est très débattue et les données pathologiques dans ce contexte manquent.

Au stade intermédiaire et en l'absence de preuves de niveau 1 d'une amélioration de la survie globale après RE (par rapport à la chimio embolisation [CE]), la CE reste l'option thérapeutique privilégiée par le BCLC et l'AASLD en raison de sa plus grande disponibilité(6). Toutefois, des essais contrôlés randomisés (ECR) (7-9) ont établi un temps de progression plus longue et une amélioration de la sécurité et de la qualité de vie après la RE par rapport à la CE.

En cas de TTVP, la RE n'est pas recommandé en raison des résultats négatifs des ECR de phase III des CHC au stade C du BCLC. Plusieurs explications ont été avancées pour justifier ces résultats négatifs, parmi lesquelles : une mauvaise sélection des patients, une courbe d'apprentissage obtenue grâce à ces essais et l'absence de dosimétrie moderne, en contradiction avec les principes de base de la radiothérapie (10, 11). L'ECR multicentrique DOSISPHERE-01 a récemment recentré l'attention sur la RE en démontrant la supériorité de la dosimétrie personnalisée sur la dosimétrie standard utilisée précédemment dans les essais de phase III négatifs. Le critère de jugement principal (réponse objective) était atteint (71% vs. 36%,  $p=0,0074$ ) lors de l'analyse intermédiaire malgré l'inclusion de tumeurs de mauvais pronostic (taille moyenne  $> 10$ cm, PVTT dans 2/3 des cas). La médiane de survie globale était plus que doublée avec la dosimétrie personnalisée (26,5 vs. 10,7 mois,  $p=0,0096$ ) et elle dépassait de loin la médiane de survie globale des CHC sous traitements systémiques, pourtant recommandés. Selon les données du SPECT-CT pré thérapeutique, la dosimétrie personnalisée visait à délivrer une dose absorbée par la tumeur plus élevée tout en conservant une réserve hépatique de  $> 30$  % (c'est-à-dire le foie non traité) pour des raisons de sécurité.

Le traitement chirurgical des CHC BCLC B ou C demeure généralement controversé (12). De plus, la résection d'un CHC de grande taille, multifocal ou avec TTVP implique fréquemment

une hépatectomie majeure, soulevant ainsi le problème supplémentaire de l'insuffisance hépatique post hépatectomie. Tout ceci peut expliquer pourquoi la RE est principalement considéré comme un traitement palliatif sans espoir de guérison dans ces tumeurs. Par conséquent, dans cette population de mauvais pronostic, on a peu de données sur la réponse histologique et le devenir des patients après une chirurgie suivant un downstaging à l'Yttrium-90 (Y90).

Dans l'étude DOSISPHERE-01, onze patients atteints de CHC non résécable (n=8/11 avec TTVP) ont subi un downstaging après RE et ont finalement été opérés (91% R0). L'expérience accumulée de la segmentectomie et de la lobectomie radicale des CHC précoces a révélé que la RE permet le contrôle tumoral, l'hypertrophie contralatérale et un test de temps intégré pour éviter la chirurgie chez les patients avec une biologie tumorale agressive (2, 13). Prises collectivement, ces données suggèrent un rôle potentiel de la RE comme stratégie de downstaging, même chez les patients atteints de CHC avec TTVP, multifocaux ou de grande taille.

L'objectif de cette étude était d'évaluer la sécurité, la réponse radiologique et histologique et le devenir des patients atteints de CHC avec des TTVP, des tumeurs multifocales ou de grande taille, qui ont été opérés après la RE utilisant une dosimétrie personnalisée.

# Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery

Mohamad Azhar Meerun<sup>1</sup>, Carole Allimant<sup>1</sup>, Benjamin Rivière<sup>2</sup>, Astrid Herrero<sup>3</sup>, Fabrizio Panaro<sup>3</sup>, Eric Assenat<sup>4</sup>, Christophe Cassinotto<sup>1</sup>, Denis Mariano-Goulart<sup>5,6</sup>, Boris Guiu<sup>1</sup>

<sup>1</sup>Department of Radiology, St-Eloi University Hospital, Montpellier, France; <sup>2</sup>Department of Liver Pathology, St-Eloi University Hospital, Montpellier, France; <sup>3</sup>Department of Liver Surgery, St-Eloi University Hospital, Montpellier, France; <sup>4</sup>Department of Oncology, St-Eloi University Hospital, Montpellier, France; <sup>5</sup>PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France; <sup>6</sup>Department of Nuclear Medicine, CHU of Montpellier, Montpellier, France

**Contributions:** (I) Conception and design: B Guiu, C Allimant, MA Meerun; (II) Administrative support: B Guiu; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: B Guiu, C Allimant, MA Meerun; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Prof. Boris Guiu, MD, PhD. Department of Radiology (Head), St-Eloi University Hospital, 80 avenue Augustin Fliche, 34295 Montpellier, France. Email: B-guiu@chu-montpellier.fr.

**Background:** Transarterial radioembolization (TARE) has recently been recognized as a bridging/downstaging therapy to surgery for early hepatocellular carcinomas (HCCs) with high rates of complete pathological necrosis (CPN) on liver explants. In patients with portal vein tumoral thrombus (PVTT), multifocal or large tumors, TARE has mainly a palliative role and surgery remains controversial in this poor-prognosis population. Personalized dosimetry recently proved to outperform standard dosimetry used in prior negative Y90 randomized-controlled trials.

**Methods:** In this retrospective study, we evaluated safety, radiological and pathological response and outcomes in HCC patients with PVTT, multifocal or large tumors, who underwent surgery after downstaging using TARE with Y90-loaded glass microspheres with personalized dosimetry.

**Results:** Between December 2015 and October 2021, eighteen unresectable patients (14/18 with PVTT) had surgery (16 resections, 2 liver transplantations) 6.2 months (range, 2–14.6 months) after a single Y90 treatment. No 90-day mortality was reported. Objective modified response criteria in solid tumors (mRECIST) response were noted in all but one patient. Complete and extensive (50–99%) necrosis was observed in 36% and 45% of tumors, respectively. The post-treatment tumor-absorbed dose significantly differed depending on the extent of pathological necrosis ( $P=0.045$ ). Median overall survival and progression-free survival (PFS) were respectively of 61.8 months [95% CI: 31.4 months–not reached (NR)] and 49.3 months (95% CI: 14 months–NR). PFS was longer in patients with complete imaging response [median not reached (none recurred or died) *vs.* 21.5 months (95% CI: 10.1 months–NR),  $P<0.001$ ] and in those with complete pathological response [median not reached *vs.* 22.5 months (95% CI: 10.1 months–NR),  $P<0.001$ ].

**Conclusions:** Y90 TARE using personalized dosimetry can provide high rates of imaging and pathological response in patients with PVTT, large or multifocal HCC. Subsequent surgery is safe and leads to outcomes far exceeding expectations in an otherwise poor prognosis population with no chance for cure.

**Trial Registration:** Clinical trial number: NCT05045573.

**Keywords:** Selective internal radiation therapy; hepatocellular carcinoma (HCC); liver cancer; resection; transplantation

Submitted May 11, 2022. Accepted for publication Aug 05, 2022.

doi: 10.21037/hbsn-22-184

View this article at: <https://dx.doi.org/10.21037/hbsn-22-184>

## Introduction

Y90 transarterial radioembolization (TARE) was recently endorsed in Barcelona clinic liver cancer (BCLC) recommendations (1), based on the results of the LEGACY study, which reported outcomes following TARE of  $\leq 8$  cm solitary hepatocellular carcinoma (HCC) comparable to those following curative-intent therapies (2). TARE was also supported by the high rate of complete pathological response in this population (3-5). On the contrary, the place of TARE in BCLC B/C HCCs and, more specifically, in large ( $> 8$  cm), multifocal HCCs or in HCCs with portal vein tumor thrombus (PVTT) is highly debated and pathological data in this context are lacking.

At intermediate stage and in the absence of level one evidence for OS improvement with TARE [*vs.* transarterial chemoembolization (TACE)], TACE is still the therapeutic option favored by BCLC and American Association for the Study of Liver Diseases (AASLD) on account of its wider availability (6). Yet, randomized-controlled trials (RCT) (7-9) established a longer time to progression (TTP) and an improved safety and quality of life after TARE *vs.* TACE.

In case of PVTT, TARE is not recommended because of negative phase III RCTs in BCLC C stage. Several explanations have been put forward to account for such negative results, among which: a poor selection of patients, a learning curve achieved through these trials and the absence of modern dosimetry, in contradiction with basic principles of radiation therapy (10,11). The DOSISPHERE-01 multicenter RCT has recently refocused attention on TARE by demonstrating the superiority of personalized dosimetry over standard dosimetry used in prior negative phase III trials. At interim analysis, the primary endpoint (objective response) was met (71% *vs.* 36%,  $P=0.0074$ ) despite the inclusion of poor-prognosis tumors (mean size  $> 10$  cm, PVTT in 2/3 cases). Median overall survival (OS) was also more than doubled with personalized dosimetry (26.5 *vs.* 10.7 months,  $P=0.0096$ ) and it far exceeded the OS following systemic treatments, albeit recommended. Based on pre-treatment single photon emission computed tomography (SPECT)-CT, personalized dosimetry aimed at delivering high tumor-absorbed dose while keeping  $> 30\%$  hepatic reserve (*i.e.*, untreated liver) for safety purposes.

Surgical treatment of BCLC B or C generally remains controversial (12). Moreover, resection of large, multifocal or PVTT HCC frequently implies a major hepatectomy, thereby raising the additional issue of insufficient future liver remnant (FLR). All this may explain why TARE is mainly considered as a palliative treatment with no hope

of cure in these tumors. Consequently, little is known in this poor prognosis population about the pathological response and patient's outcome after surgery following Yttrium-90 (Y90) downstaging. In DOSISPHERE-01, eleven patients with unresectable HCC ( $n=8/11$  with PVTT) were downstaged by Y90 and eventually underwent surgery (91% R0). The accumulated experience of radiation segmentectomy and lobectomy in early tumors revealed that Y90 allows tumor control, contralateral hypertrophy and an embedded test of time to prevent surgery in patients with aggressive tumor biology (2,13). Taken collectively, these data suggest a potential role of Y90 as a downstaging strategy, even in HCC patients with PVTT, multifocal or large tumors.

The aim of this study was to evaluate safety, radiological and pathological response and outcomes in HCC patients with PVTT, multifocal or large tumors, who underwent surgical treatment after Y90 TARE using personalized dosimetry. We present the following article in accordance with the STROBE reporting checklist (available at <https://hbsn.amegroups.com/article/view/10.21037/hbsn-22-184/rc>)

## Methods

### Patient selection

Consecutive patients who underwent TARE between December 2015 and October 2021 were included. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This retrospective study was approved by our institutional review board (IRB-UH Montpellier; accreditation number: 198711 and the IRB ID is 202100933) and written informed consent was obtained from all patients. Inclusion criteria were: HCC diagnosed by histopathology or by the imaging criteria of the European Association for the Study of the Liver (EASL); patients treated by TARE using Y90-loaded glass microspheres for a large (*i.e.*,  $> 8$  cm) and/or multifocal (all  $> 2$  cm to ensure reliable assessment of both imaging response and tumor-absorbed dose) tumor, and/or presenting PVTT; patient who underwent surgical resection or liver transplantation (LT). Exclusion criteria were: patients undergoing additional treatment (either systemic or liver-directed therapy) in the treated zone to capture the pure effects of TARE at pathology; extra-hepatic disease.

In our tertiary center, TARE is indicated in BCLC A patients with non-resectable  $\geq 5$  cm HCC, in BCLC B patients or in BCLC C patients with PVTT. In addition, the following criteria had to be fulfilled: preserved liver

function (Child-Pugh < B7), unilobar disease with sufficient hepatic reserve (>30%), ECOG 0–1, normal bilirubin level (<2 mg/dL), absence of severe renal impairment [glomerular filtration rate (GFR) <30 mL/min/1.73 m<sup>2</sup>] and absence of extrahepatic spread. Our policy granted the exception to bilobar disease when it was predominant in one lobe and thermal ablation could efficiently cure the contralateral disease. TARE either served as a bridge/downstaging therapy to surgery or as a palliative treatment in inoperable patients.

TARE was validated by a multidisciplinary tumor board dedicated to liver tumors, including interventional radiologists, hepatologists, oncologists and liver surgeons. Over the study period, our policy was to systematically consider surgery after a test-of-time period ≥3 months, provided enough FLR [standardized FLR (sFLR) ≥40%] and tumor control were achieved. LT was considered only when the tumor was downstaged without any other tumor occurrence for at least 6 months and after external experts appointed by the biomedicine agency in France had given their agreement.

#### *Pretreatment and radioembolization technique*

All patients underwent angiography and 99m-Tc-macroaggregated albumin (MAA) SPECT-CT before TARE with Y90 glass microspheres to ensure complete tumor (and PVTT, when present) targeting, while preserving as much nontumoral parenchyma as possible. The lung shunt fraction was determined, extrahepatic MAA distribution was checked and the activity required was calculated using the Medical Internal Radiation Dosimetry (MIRD) method to deliver at least 205 Gy to the tumor and >250–300 Gy if possible, while maintaining <150 Gy to whole liver, in accordance with the personalized dosimetry concept (14). A Y90-positron emission tomography (PET)/CT was systematically performed within 24 hours following TARE.

The pre- and post-treatment absorbed doses were determined from pre-TARE SPECT/CT and post-TARE Y90-PET/CT. In case of tumor multifocality, the absorbed dose delivered to each nodule was estimated for a per-tumor analysis, whereas the lowest tumor-absorbed dose among tumor nodules was recorded for a per-patient analysis.

#### *Baseline imaging and follow-up*

Baseline imaging was performed less than one month before TARE and clinical, biological and imaging [CT or magnetic

resonance imaging (MRI)] follow-up was conducted every 3 months thereafter. Adverse events related to TARE were classified according to the CTCAE 5.0 grading. Imaging review was carried out by two readers to assess imaging response upon modified response criteria in solid tumors (mRECIST), with discrepancies adjudicated by consensus. As in the LEGACY study (2), we dichotomized localized mRECIST, defined as the tumor response within the treated zone, and mRECIST, which assessed localized tumor response but also distant tumor progression.

PVTT and hepatic vein tumor thrombus (HVT) were classified as described elsewhere (15). Since PVTT/HVT are considered non-measurable upon mRECIST, we considered: (I) complete response (CR) both when tumor response (upon mRECIST) outside PVTT/HVT was complete and when PVTT displayed unenhancement on follow-up images, without any increase in its diameter and without any proximal extension; (II) progressive disease either when progression was noted (upon mRECIST) outside PVTT/HVT, or when increased diameter or extension of a contrast-enhanced PVTT was encountered; (III) partial response (PR) or stable disease (SD), as defined by mRECIST for tumor assessment outside PVTT/HVT, together with the absence of both diameter increase and proximal extension of the PVTT. The same principles were applied to localized mRECIST.


In this study, imaging response on the last follow-up preceding surgery and the best response between TARE and surgery were recorded.

#### *Surgery*

sFLR volumetric evaluations were determined using CT/MRI scans, as described elsewhere (16). Surgery was performed by experienced (10 to 20 years) liver surgeons working at our tertiary transplant center. Time from TARE to resection or transplantation, 90-day mortality, morbidity according to Dindo-Clavien classification (17) and post hepatic liver failure (PHLF) according to International Study Group of Liver Surgery (ISGLS) criteria (18) were reported.

#### *Pathology analysis*

The explant was evaluated from archived slides by one experienced (>10 years in liver pathology) pathologist for evidence of gross and histological necrosis. After formalin fixation, the resected liver was examined using 4–6 mm



**Figure 1** Study flow chart. HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombus; TARE, transarterial radioembolization.

slice thickness. For the per-tumor analysis, the percentage of necrosis was reported for each nodule and classified into three groups as previously described (3-5,19): complete pathological necrosis (CPN), extensive (50–99%) and partial (<50%) tumor necrosis. For the per-patient analysis, the poorest pathological response was considered in case of tumor multifocality. The resection margin, the degree of tumor differentiation (poor, moderate or well differentiated) and the presence of microscopic vascular emboli were also evaluated.

### Statistical analysis

Continuous variables were described using means  $\pm$  standard deviation or median and range. Median [and 95% confidence interval (CI)] follow-up was calculated using the reverse Kaplan-Meier method. Progression-free survival (PFS) was defined as the time from TARE to the first recurrence, death or last follow-up. OS was defined as the interval between TARE and death (any cause) or last follow-up. Survival curves were estimated using the Kaplan-Meier method and compared with the log-rank test. A

robust variance estimator was used systematically. All the analyses were performed with the Stata software, version 16.1 (Stata corporation, College Station, TX, USA). A P value <0.05 was considered significant.

## Results

### Population (Figure 1)

Over the study period, 116 patients underwent TARE with Y90 glass microspheres. Ninety-two had HCC, among whom 25 (27%) were surgically-treated (22 resections and 3 LT). The main reasons for unresectability included progressive disease after TARE, severe portal hypertension precluding resection, severe renal, respiratory or cardiac impairment, advanced age and patient's refusal. Two surgically-treated patients did not meet the inclusion criteria because they had neither PVTT, nor large or multifocal HCC. Four patients were excluded because they had received additional treatments prior to surgery. One patient was diagnosed with hepatocholangiocarcinoma on the final pathology report and was therefore excluded.

Overall, 18 patients were included in our series. Baseline

**Table 1** Baseline characteristics of patients at TARE treatment (n=18)

Variables	Values
Age (years)	68 [49–85]
Sex	
Male	16 [89]
Female	2 [11]
Underlying liver disease	
HVC/HVB	4 [22]
OH	7 [39]
NASH	6 [33]
No liver disease	1 [6]
AFP (ng/mL)	16 [2–3,071]
Child-Pugh score	
A5	16 [89]
A6	2 [11]
MELD score	7 [6–16]
ECOG	
0	9 [50]
1	9 [50]
BCLC stage	
A	1 [6]
B	3 [17]
C	14 [78]
Treatment before TARE	
TACE <sup>†</sup>	1 [25]
TA + TACE <sup>‡</sup>	1 [25]
Systemic treatment	1 [25]
Segmentectomy	1 [25]
Index tumor size (mm)	53 [20–150]
Tumor distribution	
Unilobar	17 [94]
Bilobar	1 [6]
PVTT type (15)	
VP4	1 [7]
VP3	5 [36]
VP2	7 [50]
VP1	1 [7]

**Table 1** (continued)**Table 1** (continued)

Variables	Values
HVTT type (15)	
VV1	2 [67]
VV2	1 [33]
PVTT or HVTT	15[83]

The data are expressed as n [%] or median [range]. <sup>†</sup>, TACE was performed 4 years before TARE and TARE was performed outside the initial TACE anatomical territory; <sup>‡</sup>, TACE was performed 2 years before TARE and TARE was performed outside the initial TACE anatomical territory. TARE, transarterial radioembolization; HVC, hepatitis C; HVB, hepatitis B; OH, alcoholic cirrhosis; NASH, non-alcoholic steatohepatitis; AFP, alpha fetoprotein; MELD, model for end-stage liver disease; ECOG, eastern cooperative oncology group; BCLC, Barcelona clinic liver cancer; TACE, transarterial chemoembolization; TA, thermal ablation; PVTT, portal vein tumoral thrombus; HVTT, hepatic vein tumor thrombus.

patient, tumor and treatment characteristics are summarized in *Table 1*. Fourteen (78%) had PVTT, 2 (11%), multifocal disease and 5 (28%) large lesions. One multifocal patient had 2 tumors (with a sum of diameters of 82 mm) and the other, 3 tumors (with a sum of diameters of 110 mm). Overall, 83% (15/18) of the population had macrovascular invasion (PVTT or HVT). Three patients with PVTT also had large (>8 cm) tumors. No patient with multifocality had PVTT or large lesions. Three patients (17%) had HVT, which was associated with PVTT in 2/3 patients. A total of 22 tumors were available for per-tumor analysis. One patient had bilobar disease but received percutaneous thermal ablation in the contralateral lobe concurrently to TARE.

### **TARE and related events**

Most patients (13/18) received lobar TARE [right (n=10), left (n=3)], and the remaining patients underwent sectorial and segmental TARE for two and three of them, respectively. Baseline total tumor volume was 82 mL (range, 15–1,769 mL) and baseline perfused-liver volume was 677 mL (range, 265–2,331 mL). A discrepancy between pre-treatment SPECT-CT estimated dosimetry and post-treatment PET-CT results was noticed in two patients: one had a preferential flow in the non-tumor-bearing segment due to vasospasm, which resulted in a poor tumor dose on the post-treatment PET-CT. The other patient had less

**Table 2** Perioperative data

Surgical data	Values
Clavien-Dindo classification	
3b	
Hemorrhagic complications requiring reintervention under GA	1 [6]
Post operative wound requiring reintervention under GA	1 [6]
Post operative wound dehiscence	1 [6]
Biloma requiring intervention under GA	2 [12]
4b (hemorrhagic shock)	1 [6]
Blood loss (mL)	700 [300–2,000]
90-day mortality	0
PHLF	
Absent	14 [78]
Grade A	0
Grade B (clinical ascites)	2 [11]
Grade C	0
Not applicable (liver transplantation)	2 [11]
Hospital stays (days)	12 [7–51]
ICU stays (days)	6 [1–25]

The data are expressed as n [%] or median [range]. GA, general anaesthesia; PHLF, post hepatectomy liver failure; ICU, intensive care unit.

radiation delivered to the proximal portion of the portal vein thrombosis without any technical explanation. TARE-related adverse events were all mild and transient (Table S1). No radioembolization-induced liver disease (REILD) or pneumonitis was observed. Baseline and pre-operative data on biochemical liver function tests are collected in Table S2.

### Tumor response

#### Localised mRECIST

Seven (39%) patients achieved CR prior to surgery, whereas 10 (56%) achieved PR and 1 (6%) had SD. Response rates were identical when considering the last follow-up preceding surgery and the best response between TARE and surgery. The median time to achieve best response was 3 months (range, 2–11 months).

#### mRECIST

CR prior to surgery was noted in 7/18 (39%) patients, PR in 8/18 (44%), SD in 1/18 (6%) patients and progressive disease in 2/18 (11%) patients. Progressive disease occurred in the untreated zone and was accessible to a curative treatment. Both patients received intraoperative thermal ablation during surgery. Considering the best response between TARE and surgery, CR was noted in 7/18 (39%) patients, PR in 10/18 (56%) patients and SD in 1/18 (6%) patient.

Median baseline alpha fetoprotein (AFP) was 16.2 ng/mL (range, 2.2–3,071 ng/mL) and AFP 3 months after TARE was 12.9 ng/mL (range, 1.7–85 ng/mL) [P= not significant (NS)]. Data specific to patients with PVTT are summarized in Table S3.

#### Surgery

Eleven patients underwent major hepatectomy (Brisbane classification), 2 received LT and 5 patients had less extended resections. In patients who underwent major hepatectomy, volumetric evaluations showed a median sFLR of 48% (range, 36–70%) at baseline and 67% (range, 48–107%) the week preceding surgery, which determined a median FLR hypertrophy of 36% (range, 4–81%).

The median time from TARE to surgery was 6.2 months (range, 2–14.6 months). The most common treatment was right hemi-hepatectomy (11/18). The other patients underwent left lobectomy (n=3), segmentectomy (n=1), bi-segmentectomy with additional wedge resection (n=1) and LT (n=2). Parenchymal dissections were performed using CUSA Dissectron® (Integra Life Sciences Corp., Tokyo, Japan) in all cases of resection. Of note, the transplanted patients both presented PVTT at baseline. Median surgery time was 406 minutes (range, 232–672 minutes). Perioperative data are collected in Table 2. Overall, 33% (n=6) ≥ grade III Dindo-Clavien complications were recorded. Two grade B PHLF occurred with full recovery after diuretic therapy. No 90-day mortality was observed.


#### Pathological results

All patients had R0 resection. In per-tumor analysis (n=22), CPN, extensive necrosis and partial necrosis were achieved respectively in 8 (36%), 10 (45%) and 4 (18%) tumors. In per-patient analysis, CPN, extensive necrosis and partial

**Table 3** Dosimetric and pathologic response association

Variables	CPN	Extensive	Partial	P value
Tumor absorbed-dose (Y90 PET-CT)	446 [293–1,131]	320 [169–678]	187 [31–340]	0.045*
Tumor absorbed-dose (MAA SPECT-CT)	458 [295–967]	363 [205–615]	400 [221–414]	0.320

The data are expressed as median [range]. \*,  $P < 0.05$ . PET, positron emission tomography; SPECT, Single photon emission computed tomography; CT, computed tomography; CPN, complete pathological necrosis; MAA, macro-aggregated albumin; Y90, yttrium 90.



**Figure 2** Association between pathological necrosis and post-treatment tumor-absorbed dose. CPN, complete pathological necrosis; CT, computed tomography; PET, positron emission tomography.

necrosis occurred respectively in 28%, 50% and 22% of patients. Microscopic vascular emboli were reported in 6/18 (33%) patients. Evaluation of cellular differentiation was possible in 12/18 patients (5 had no residual viable tumor cells and one presented extensive necrosis devoid of viable cells for tumor grading). Tumors were well-, moderately-, and poorly-differentiated in 1, 5, and 6, respectively.

Median tumor size was 37 mm (range, 20–93 mm) in tumors showing CPN, 65 mm (range, 34–111 mm) in those with extensive necrosis and 56 mm (range, 29–150 mm) in case of partial necrosis ( $P=0.24$ ). Baseline AFP levels were highest in patients with CPN with a median of 38 ng/mL (range, 3.5–3,071 ng/mL) ( $P=0.7$ ). Median AFP levels in patients with extensive and partial necrosis were 15 ng/mL (range, 2.2–1,032 ng/mL) and 16 ng/mL (range, 3.4–16.7 ng/mL) respectively ( $P=0.7$ ). All patients presenting CPN had PVT at baseline. In PVT patients, 36% (5/14) exhibited CPN and none presented microscopic vascular emboli on the explant. Of note, 79% (11/14) exhibited CPN of the PVT.

### Dosimetric considerations

The whole liver-absorbed dose was 99 Gy (range, 30–150 Gy). Post-treatment perfused-liver dose was 202 Gy (range, 123–650 Gy). In per-tumor analysis, the median pre- and post-treatment tumor-absorbed doses were 386 Gy (range, 169–967 Gy) and 331 Gy (range, 31–1,131 Gy) respectively. Tumor-absorbed doses were greater in patients presenting CPN (Table 3). Post-treatment tumor-absorbed dose significantly differed in tumors that exhibited complete (446 Gy), extensive (320 Gy) and partial (187 Gy) pathological necrosis ( $P=0.045$ ) (Figure 2).

### Radiologic-pathologic correlation (Table 4)

All patients (5/5) with CPN had CR according to best mRECIST response. Conversely, 71% (5/7) of patients with CR according to best mRECIST response achieved CPN. The remaining patients (2/7) with CR had extensive tumor necrosis at pathology.

### Time to surgery and pathological necrosis

Median time from TARE to surgery was 8.3 months (range, 5.8–14.6 months) in patients with CPN, 4.3 months (range, 3.7–13.6 months) in patients with extensive necrosis and 4.9 months (range, 2.1–10.5 months) in patients with partial necrosis. Delay from TARE to surgery was longer in CPN patients ( $P=0.05$ ).


### Patient's outcome (Figure 3)

During a median follow-up of 29.6 months (95% CI: 15.4–32.9 months), 4/18 patients died and 7/18 (39%) patients recurred, which determined a median PFS of 49.3 months (95% CI: 14 months–NR) and a median OS of 61.8 months (95% CI: 31.4 months–NR) (Table 5). PFS at 1 and 2 years were 82.6% (95% CI: 55.3–94.1%) and 58.9%

**Table 4** Response according to localized mRECIST and pathological necrosis

Variables	Complete response	Partial response	Stable disease
CPN (n=5)	5 [100]	0	0
Extensive (n=9)	2 [22]	7 [78]	0
Partial (n=4)	0	3 [75]	1 [25]

The data are expressed as n [%]. CPN, complete pathological necrosis; mRECIST, modified response evaluation criteria in solid tumors.



**Figure 3** Overall (A) and progression-free (B) survivals in the whole cohort. Progression-free survival according to complete radiologic response status (C) and complete pathological necrosis status (D). CR, complete response; CPN, complete pathological necrosis; mRECIST, modified response criteria in solid tumors; TARE, transarterial radioembolization.

(95% CI: 29.3–79.6%), respectively. OS at 1 and 2 years were 93.8% (95% CI: 63.2–99.1%) and 85.9% (95% CI: 54–96.3%), respectively. HCC-related mortality was 1/18. Relapse location and the outcomes of recurring patients are summarized in *Table 6*. Causes of death in non-relapsing patients were: sudden cardiac arrest (1 patient, 7 months after LT) without any tumor relapse, severe cryptococcal meningitis (1 patient, 7 months after surgery) and septic choc (1 patient, 16.8 months after surgery).

Of note, one patient had a nodular implant in the right ventricle, whose metastatic nature was confirmed on biopsy. Interestingly the patient had an initial right HVT. The two

other patients with HVT did not develop lung metastasis after a 27- and 28-month follow-up, although one relapsed within the liver. The non-recurring HVT patient also presented PVTT at baseline but achieved CPN.

All 3 patients with incomplete pathological response on the PVTT recurred. Among 7 patients with microscopic vascular emboli, 57% (4/7) recurred.

Among 7 recurring patients, 86% (6/7) remained eligible either to a new curative treatment or to a systemic therapy, whereas one had supportive care due to old age. Two patients underwent additional surgery upon first relapse (LT and segmentectomy, respectively). Three patients received

Table 5 Patient characteristics and outcomes

Patient	PVTT (15)	HVT (15)	Baseline AFP (ng/mL)	Index tumor size (mm)	Best mRECIST response <sup>†</sup>	PN	MVE	Post-treatment tumor-absorbed dose (Gy)	TTS (months)	TTR (months)
1	VP2	–	15.6	89	CR	Extensive	1	225	13.6	49.3
2	VP4	–	44.2	111	PR	Extensive	0	169	8	21.5
3	VP2	–	3,071	93	CR	CPN	0	304	5.8	–
4	VP3	–	1,032	50	PR	Extensive	1	186	4.2	–
5	VP2	–	3.4	32	SD	Partial	0	31	2.1	–
6	VP3	–	7.5	47	PR	Extensive	0	322	4.1	10.3
7	VP2	–	38.4	41	CR	CPN	0	394	7.8	–
8	VP1	VV2	72.2	42	CR	CPN	0	388	8.3	–
9	VP2	–	15.4	37	PR	Extensive	1	396	3.7	14
10	VP2	VV1	2.2	77	PR	Extensive	1	318	7.2	22.5
11	–	VV1	61	37	PR	CPN	0	515	6.2	7.4
				29	–	Partial	–	148	–	–
				34	–	Extensive	–	382	–	–
12	VP3	–	3.5	20	CR	CPN	0	1,131	14.6	–
13	–	–	16.7	26	PR	CPN	1	497	10.5	–
				56	–	Partial	–	340	–	–
14	–	–	12.5	150	PR	Partial	1	225	3.5	10.1
15	VP3	–	13.1	26	CR	CPN	0	293	9.7	–
				37	–	CPN	–	506	–	–
16	–	–	60	91	CR	Extensive	0	311	4.3	–
17	VP3	–	13.7	55	PR	Extensive	0	678	6.2	–
18	VP2	–	69.8	74	PR	Extensive	0	655	3.9	–

<sup>†</sup>, best mRECIST response = best localized mRECIST response = localized mRECIST response prior to surgery. PVTT, portal vein tumoral thrombosis; HVT, hepatic vein thrombosis; AFP, alpha fetoprotein; mRECIST, modified response evaluation criteria in solid tumors; CR, complete response; PR, partial response; SD, stable disease; MVE, microvascular embolism; TTS, time to surgery; TTR, time to recurrence; PN, pathological necrosis; CPN, complete pathological necrosis; VP1, tumor thrombus distal to the second-order branches of portal vein; VP2, invasion of the second-order branches of portal vein; VP3, thrombus in the first-order branches; VP4, tumor thrombus in main portal trunk or portal branch contralateral to primarily involved lobe (or both); VV1, tumor thrombus in a branch of the hepatic vein; VV2, tumor thrombus in the main trunk of the hepatic veins; VV3, thrombus reaching the right atrium.

systemic therapy. One patient underwent transarterial chemo-infusion and thermal ablation and is currently awaiting LT after achieving SD.

#### *Patient's outcome stratified by imaging and pathological response (Figure 4)*

While median PFS was not reached (no recurrence, no death


during following) in patients with CPN and in those with CR on imaging, it amounted respectively to 22.5 months (95% CI: 10.1 months–NR) and to 21.5 months (95% CI: 10.1 months–NR) in the others (P<0.001).

Only one patient with CR as best response (1/7; 14%) recurred at 4 years, whereas 55% of patients (6/11) with PR or SD relapsed [median time to recurrence: 1 year (range, 0.6–1.8 years)]. No patients with CPN recurred [median

**Table 6** Relapse location and outcome of recurring patients

Patients	Relapse location	Treatment	Outcome
1	Liver followed by pulmonary and lymph nodes metastases	Segmentectomy, systemic treatment <sup>†</sup> , followed by supportive care	HCC-related mortality due to rapidly progressive disease
2	Simultaneous liver and bone metastases	Bevacizumab and atezolizumab; radiation therapy in the localized bone metastasis	Complete radiologic response
3	Cardiac metastasis	Systemic treatment <sup>‡</sup>	Awaiting treatment evaluation
4	Liver	TACI followed by PTA	Awaiting for LT
5	Liver	Sorafenib followed by bevacizumab and atezolizumab	Stable disease
6	Liver	LT	Mortality related to a sudden cardiac arrest
7	Liver	Supportive care	–

<sup>†</sup>, Nexavar followed by Lenmiva; <sup>‡</sup>, pembrolizumab due to a synchronous lingual tumor. HCC, hepatocellular carcinoma; TACI, transarterial chemo-infusion; PTA, percutaneous thermal ablation; LT, liver transplantation.



**Figure 4** Example of a patient of our series showing baseline images of the tumor (star) and PVTT (arrow) (A) with complete targeting on the pre-treatment SPECT-CT (B) and post-treatment PET-CT (678 Gy) (C), complete radiologic response on the tumor (hollow star) and PVTT (hollow arrow) prior to surgery (D) and liver explant (E). A, anterior; P, posterior; CT, computed tomography; PVTT, portal vein tumor thrombus; SPECT, single photon emission computed tomography.

time to recurrence in patients without CPN: 1.2 years (range, 0.6–4.1 years)].

## Discussion

The present study shows that successful downstaging of poor-prognosis HCCs can potentially be achieved by Y90 TARE with personalized dosimetry, which yields a high rate of imaging and pathological response. The potential of TARE to successfully bridge/downstage to LT or resection has been widely demonstrated in early HCC, especially through radiation lobectomy (20) and segmentectomy (2). In this context, pathological data have revealed high rates of CPN for small, solitary and treatment-naïve tumors (3–5,19). Our cohort has brought up new data in HCC with PVTT, multifocal disease and large tumors. At baseline, the HCCs in our series were all unresectable and not only outside conventional criteria for LT including the AFP model and Milan criteria, but also outside the extended University of California San Francisco (UCSF) criteria. They were however successfully downstaged using only one single Y90 treatment.

According to AASLD/BCLC (1,21), PVTT patients should undergo systemic therapy, whereas patients with multifocal or large HCCs should be considered for TACE (and optionally for TARE); either for palliative care or as a downstaging strategy to LT. We observed a median OS and PFS of respectively 61.8 months and 49.3 months in our cohort, including 78% of patients with PVTT. These survival outcomes far exceed expectations in this poor prognosis population: the results of systemic therapies in this context are considerably worse, as illustrated by the median OS and TTP of respectively 8.1 months and 4.1 months after sorafenib (SHARP trial) (22), and by the 14.2-month median OS and the 6.7-month PFS after atezolizumab-bevacizumab (IMBRAVE150 trial) (23). Upfront surgical resection of PVTT HCC usually results in poor outcome (24) and was shown to perform no better than sorafenib (25). Even in expert centers and with progressive refinements in dosimetry, TARE used as a palliative treatment provides a median OS ranging from 16.6 to 32 months in Child-Pugh A patients with branch PVTT (26–29). Therefore, our results suggest an improved outcome of TARE downstaging to surgery over systemic therapy or upfront surgery or TARE alone.

### Safety of TARE and surgery

Regarding safety, only mild and transient adverse events

were reported in our series after TARE, in keeping with the literature (5,14). As previously reported (20), surgeons could easily differentiate the TARE-treated liver from the untreated liver due to increased inflammation and induration, but they noticed frequent adhesions to adjacent structures which may have complicated surgical resection. Nevertheless, surgery after TARE was safe in our cohort with no 90-day mortality, no grade C PHLF and a 33% rate of  $\geq$  III Dindo-Clavien complications. Perioperative outcomes remained within the range reported for surgical resection without prior TARE (30).

### Pathological response

Despite high tumor burden and poor prognosis of our HCC series, CPN occurred after Y90 alone in a significant number of tumors (36%). Of note, all CPN occurred in PVTT HCC, suggesting that PVTT can be completely cured by TARE using personalized dosimetry. Higher rates (47–68%) were reported in pathological series after radiation segmentectomy, but only early HCCs were involved (3–5). Not only did our cohort present frequent PVTT, but the median tumor size was also twice as large (5.3 *vs.* 2.3–2.6 cm) as that of the previous series. In a series including 5/38 patients with PVTT (19), CPN was reported in 33% of >5 cm tumors, in line with our findings. The larger the tumor, the lower the chance of CPN, due to dose deposition heterogeneity and/or difficulty to reach an efficient dose threshold while keeping safe whole-liver absorbed dose. Not surprisingly, tumors achieving CPN received a significantly greater radiation dose than the others (446 Gy for CPN, 320 Gy and 187 Gy for extensive and partial necrosis respectively,  $P=0.045$ ) on post-TARE Y90-PET/CT, reflecting the actual dose delivered to the tumor. Similar findings have been reported in T1–T2 solitary (3,5) or T2–T3 (4) HCC.

Achieving CPN after pretransplant locoregional therapies heralds lower recurrence and better survival in LT recipients compared to those exhibiting partial necrosis (31,32). Gabr *et al.* (20) identified pathological necrosis as a significant prognosticator of recurrence in 31 HCC patients (only one with PVTT) undergoing surgical resection after TARE. In our series of HCC with PVTT, large, or multifocal tumors, no patient with CPN recurred during follow-up, whereas median PFS was 22.5 months in those who did not achieve CPN ( $P<0.001$ ). Therefore, our findings also support pathological necrosis as a predictor of recurrence in this specific population.

### **Imaging response**

In our series, the best objective response rate (ORR) was obtained at 3 months. While upon localized mRECIST, ORR was high, i.e., 94% (39% CR, 52% PR), it amounted to 83% upon mRECIST (39% CR, 44% PR), thereby confirming the great potential of TARE as a downstaging strategy. A significant correlation between imaging and pathological response has been shown after radiation segmentectomy (22,31,32). Predicting CPN would be highly desirable to avoid unnecessary surgical resection; it is however beyond the scope of our study. Interestingly, all patients presenting CPN after surgery had prior CR on imaging. Conversely, among patients with CR, 71% (5/7) had CPN. Patients with CR on imaging had longer PFS than the others ( $p < 0.001$ ), with only one CR patient recurring at 4 years, whereas 55% of PR/SD patients relapsed at a median time of one year. Taken collectively, these data support referring to surgery the patients exhibiting CR on imaging at 3 months.

### **Resection or LT after Y90 downstaging**

In a very recent study assessing TARE in PVTT patients ( $n=17$ ) as a downstaging strategy to LT (33), the intention-to-treat analysis showed that only 29% (5/17) actually received LT roughly 2 years after TARE. This long delay is accounted for by the  $\geq 6$ -month duration of sustained radiological response which is required before patients gain HCC exception points. Among them, 3 had tumor recurrence within 1 year of LT. In this study, a median PFS of 12.1 months after TARE was reported in the whole cohort, 34.6 months in transplanted and 10.3 months in non-transplanted patients. Our results outperform these findings with a 49.1% median PFS and OS rates comparable to those of this study's transplanted patients, which suggests that resection should be favored whenever possible, keeping LT for non-resectable patients ( $n=2$  in our series) or as salvage therapy, especially in the current context of graft shortage.

Additionally, Serenari *et al.* (33) raised the ethical issue of the use of deceased donors for HCC patients with macrovascular invasion, given the high recurrence rate [60% in deceased donor liver transplantation (DDLT)] in their cohort. This addresses the important question of appropriate patient selection for surgery. Downstaging/bridging using Y90 TARE basically carries an embedded test of time over several months, particularly useful to select less

aggressive tumors (34). In contrast with systemic therapies, the simulation phase based on 99m-Tc MAA SPECT-CT as part of TARE, provides both an accurate patient selection and a really personalized approach. Interestingly, Y90 also causes contralateral hypertrophy of the untreated FLR during the waiting period, allowing patients to reach safe volumetric thresholds to perform resection (13,35). The median time from radioembolization to surgery was 6.2 months in our cohort, in line with data found in the literature (4,19). The optimal time from Y90 treatment to resection remains debated (35,36), reflecting the complex balance between a higher chance to select patients with limited tumor aggressiveness and higher risks to lose a chance for cure. The existence of a temporal effect between TARE and tumor necrosis has been suggested, a longer time allowing for an optimal cytotoxic effect (4,19). This is also supported by our findings of a longer delay between Y90 and resection in patients presenting CPN *vs.* the others. Nevertheless, the best tumor response on imaging was noted at 3 months.

### **Timing for resection after Y90**

The nontreated liver volume steadily increased over the 6 months following Y90 TARE, in line with previous reports (13,35). All patients reached safe sFLR volume threshold. Nevertheless, we observed two cases of grade A–B PHLF. This might be explained by discrepancies between liver volume and function, as shown in a recent study on functional changes evaluated on 99m-Tc mebrofenin scintigraphy after Y90 with personalized dosimetry (37). Functional data highlighted a significant decrease of FLR function until 2–3 months after Y90. Such volume/function discrepancy had already been reported in other liver regeneration strategies, such as after portal vein embolization (PVE) (38) or after associating liver partition and portal vein ligation (ALPPS) (39). As after ALPPS, during the first 3 months following Y90, the FLR (i.e., nontreated liver) volume overestimated its function, which could lead to unsafe liver resection caused by insufficient FLR function. Thus, waiting at least 3 months after Y90 would be advisable both to restore baseline whole liver function and to benefit from contralateral functional liver regeneration (37). The optimal test-of-time period should therefore range between 3 to 6 months.

This study is subject to strengths and limitations. The strengths lie first in our reporting on an HCC population with poor prognosis and no hope of cure

according to current AASLD and BCLC guidelines. Second, we used pathology results as gold standard by selecting patients treated by Y90 using glass microspheres without concomitant treatment—whether systemic or locoregional—making it possible to capture the pure effects of TARE using personalized dosimetry. Limitations include the retrospective design, the absence of control arm and the small sample size. However, this is the largest study published to date in surgically-treated patients with PVTT, large or multifocal HCC after Y90, with a comprehensive analysis including dosimetric, safety, imaging, pathological and outcome data. Finally, an intention-to-treat analysis was not provided, since only the patients who underwent Y90 TARE and, subsequently, surgery was evaluated.

In conclusion, Y90 TARE using personalized dosimetry can provide high rates of imaging and pathological response in patients with PVTT, large or multifocal HCC. Subsequent surgery is safe and leads to outcomes that far exceed expectations in a population with an otherwise poor prognosis and no chance for cure. This study supports further trials to evaluate the potential benefit in this selected population of Y90 TARE downstaging followed by surgery over currently recommended systemic therapies.

### Acknowledgments

The authors thank Sandrine Guinodéau for revising the English.

*Funding:* None.

### Footnote

*Reporting Checklist:* The authors have completed the STROBE reporting checklist. Available at <https://hbsn.amegroupp.com/article/view/10.21037/hbsn-22-184/rc>

*Data Sharing Statement:* Available at <https://hbsn.amegroupp.com/article/view/10.21037/hbsn-22-184/dss>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://hbsn.amegroupp.com/article/view/10.21037/hbsn-22-184/coif>). FP and BG serve as unpaid editorial board members of Hepatobiliary Surgery and Nutrition. CA and BG report receiving consulting fees from Boston scientific as consultants, and receiving payment from Boston scientific for presentations. The other authors have no conflict of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by our institutional review board (IRB - UH Montpellie; accreditation number: 198711 and the IRB ID is 202100933) and written informed consent was obtained from all patients.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

### References

1. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J Hepatol* 2022;76:681-93.
2. Salem R, Johnson GE, Kim E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. *Hepatology* 2021;74:2342-52.
3. Gabr A, Riaz A, Johnson GE, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. *Eur J Nucl Med Mol Imaging* 2021;48:580-3.
4. Toskich B, Vidal LL, Olson MT, et al. Pathologic Response of Hepatocellular Carcinoma Treated with Yttrium-90 Glass Microsphere Radiation Segmentectomy Prior to Liver Transplantation: A Validation Study. *J Vasc Interv Radiol* 2021;32:518-526.e1.
5. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. *Hepatology* 2014;60:192-201.
6. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018;68:723-50.

7. Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. *Liver Int* 2015;35:1715-21.
8. Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. *Gastroenterology* 2016;151:1155-1163.e2.
9. Dhondt E, Lambert B, Hermie L, et al. 90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. *Radiology* 2022;303:699-710.
10. Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2021;18:293-313.
11. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. *Hepatology* 2018;68:1429-40.
12. Allaire M, Goumard C, Lim C, et al. New frontiers in liver resection for hepatocellular carcinoma. *JHEP Rep* 2020;2:100134.
13. Lewandowski RJ, Donahue L, Chokechanachaisakul A, et al. (90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. *J Surg Oncol* 2016;114:99-105.
14. Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. *Lancet Gastroenterol Hepatol* 2021;6:17-29.
15. Cerrito L, Annicchiarico BE, Iezzi R, et al. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. *World J Gastroenterol* 2019;25:4360-82.
16. Ribero D, Chun YS, Vauthey JN. Standardized liver volumetry for portal vein embolization. *Semin Intervent Radiol* 2008;25:104-9.
17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205-13.
18. Fukushima K, Fukumoto T, Kuramitsu K, et al. Assessment of ISGLS definition of posthepatectomy liver failure and its effect on outcome in patients with hepatocellular carcinoma. *J Gastrointest Surg* 2014;18:729-36.
19. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. *Hepatology* 2009;49:1185-93.
20. Gabr A, Abouchaleh N, Ali R, et al. Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. *J Vasc Interv Radiol* 2018;29:1502-1510.e1.
21. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology* 2018;67:358-80.
22. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. *J Hepatol* 2012;57:821-9.
23. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. *J Hepatol* 2022;76:862-73.
24. Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. *Ann Surg* 2013;257:929-37.
25. Costentin CE, Decaens T, Laurent A, et al. Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. *Liver Int* 2017;37:1869-76.
26. Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. *Eur J Nucl Med Mol Imaging* 2013;40:1057-68.
27. Garin E, Rolland Y, Pracht M, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization. *Liver Int* 2017;37:101-10.
28. Spreafico C, Sposito C, Vaiani M, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. *J Hepatol* 2018;68:724-32.
29. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-

- term outcomes. *Gastroenterology* 2010;138:52-64.
30. Gelli M, Sebahg M, Porcher R, et al. Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation. *Ann Surg* 2020;272:820-6.
  31. DiNorcia J, Florman SS, Haydel B, et al. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. *Ann Surg* 2020;271:616-24.
  32. Ravaioli M, Grazi GL, Ercolani G, et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. *Transplantation* 2004;78:1780-6.
  33. Serenari M, Cappelli A, Cucchetti A, et al. Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. *Liver Transpl* 2021;27:1758-66.
  34. Titano J, Noor A, Kim E. Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. *Semin Intervent Radiol* 2017;34:109-15.
  35. Palard X, Edeline J, Rolland Y, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. *Eur J Nucl Med Mol Imaging* 2018;45:392-401.
  36. Madoff DC, Odisio BC, Schadde E, et al. Improving the Safety of Major Resection for Hepatobiliary Malignancy: Portal Vein Embolization and Recent Innovations in Liver Regeneration Strategies. *Curr Oncol Rep* 2020;22:59.
  37. Allimant C, Deshayes E, Kafrouni M, et al. Hepatobiliary Scintigraphy and Glass 90Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Nontreated Liver. *Diagnostics (Basel)* 2021;11:931.
  38. de Graaf W, van Lienden KP, van den Esschert JW, et al. Increase in future remnant liver function after preoperative portal vein embolization. *Br J Surg* 2011;98:825-34.
  39. Olthof PB, Tomassini F, Huespe PE, et al. Hepatobiliary scintigraphy to evaluate liver function in associating liver partition and portal vein ligation for staged hepatectomy: Liver volume overestimates liver function. *Surgery* 2017;162:775-83.

**Cite this article as:** Meerun MA, Allimant C, Rivière B, Herrero A, Panaro F, Assenat E, Cassinotto C, Mariano-Goulart D, Guiu B. Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery. *Hepatobiliary Surg Nutr* 2022. doi: 10.21037/hbsn-22-184

**Table S1** TARE-related adverse events

Adverse events	CTCAE grade	Outcome
Transient increase in serum bilirubin levels	Grade 1 (n=2)	Favorable outcome without any treatment
Lymphocytopenia	Grade 1 (n=7)	Favorable outcome without any treatment
	Grade 2 (n=2)	
	Grade 3 (n=4)	
Radioembolization-induced gastric ulcers	Grade 2 (n=2 <sup>†</sup> )	Favorable outcome with medical treatment

<sup>†</sup>, one patient had a right flow redistribution during a left lobar treatment and the other patient had an accessory pyloric artery not seen during the pretreatment phase. CTCAE, common terminology criteria for adverse events; TARE, transarterial radioembolization.

**Table S2** Baseline and pre-operative data on biochemical liver function tests and CHILD/MELD scores

Variables	Baseline values	Pre-operative values
Biological data		
PT (%)	84 [47–100]	91 [40–100]
Albumin (g/L)	43 [36–49]	42 [34–48]
Platelets (cells/ $\mu$ L)	184 [55–462]	161 [53–321]
Bilirubin levels ( $\mu$ mol/L)	10.5 [6–36]	9 [3–51]
AST (UI/L)	42 [17–140]	27 [18–79]
ALT (UI/L)	33 [11–143]	25 [11–120]
Child-Pugh score	5 [5–6]	5 [5–7]
MELD score	7 [6–16]	7 [6–18]

The data are expressed as n [%] or median [range]. PT, prothrombin time; AST, aspartate transaminase; ALT, alanine transaminase; MELD, Model for End-Stage Liver Disease.

**Table S3** Data specific to patients with portal vein tumoral thrombus

Variables	Values
Surgery type	
Liver transplantation	2 [14]
Right hepatectomy	8 [57]
Left lobectomy	2 [14]
Less extended surgery	2 [14]
AFP	
Baseline	15.5 [2.2–3,071]
3 months after TARE	11 [1.9–85]
Tumor absorbed dose (Gy)	
Pre-treatment SPECT-CT	320 [31–1,131]
Post-treatment PET-CT	377 [170–967]
Localized mRECIST	
CR	6 [43]
PR	7 [50]
SD	1 [7]
mRECIST	
CR	6 [43]
PR	5 [36]
SD	1 [7]
PD	2 [14]
Pathological necrosis	
CPN	5 [36]
Extensive	8 [57]
Partial	1 [7]
Microvascular emboli	4 [29]
Incomplete pathological necrosis on the PVTT	3 [21]
Time to surgery (months)	6.7 [2.1–14.6]
Recurring patients	5 [36]
Time to recurrence (months)	21.5 [10.3–49.3]
Deceased patients	4 [29]

The data are expressed as n [%] or median [range]. AFP, alpha fetoprotein; PET, positron emission tomography; SPECT, Single photon emission computed tomography; CT, computed tomography; mRECIST, modified response evaluation criteria in solid tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PVTT, portal vein tumor thrombus; TARE, transarterial radioembolization; CPN, complete pathological necrosis.

## SERMENT

- *En présence des Maîtres de cette école, de mes chers condisciples et devant l'effigie d'Hippocrate, je promets et je jure, au nom de l'Être suprême, d'être fidèle aux lois de l'honneur et de la probité dans l'exercice de la médecine.*
- *Je donnerai mes soins gratuits à l'indigent et n'exigerai jamais un salaire au-dessus de mon travail.*
- *Admis (e) dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés, et mon état ne servira pas à corrompre les mœurs, ni à favoriser le crime.*
- *Respectueux (se) et reconnaissant (e) envers mes Maîtres, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères.*
- *Que les hommes m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couvert (e) d'opprobre et méprisé (e) de mes confrères si j'y manque.*

## RÉSUMÉ

### Contexte

La radio-embolisation (RE) a récemment été reconnue comme un traitement d'accompagnement à la chirurgie pour les carcinomes hépatocellulaires (CHC) précoces avec des taux élevés de nécrose histologique complète (NHC). Chez les patients avec un thrombus tumoral de la veine porte (TTVP), des tumeurs multifocales ou de grandes tailles, la RE a principalement un rôle palliatif et la chirurgie reste discutable.

### Méthodes

Dans cette étude rétrospective, nous avons évalué la tolérance, la réponse radiologique, la réponse histologique et la survie des patients atteints de CHC avec des TTVP, des tumeurs multifocales ou de grande taille, opérés après RE avec une dosimétrie personnalisée.

### Résultats

Entre décembre 2015 et octobre 2021, dix-huit patients (14/18 avec TTVP) ont été opérés après RE. Aucune mortalité à 90 jours n'a été rapportée. Le taux de réponse objective radiologique était de 95 %. Une NHC et une nécrose histologique étendue (50-99%) ont été observées respectivement dans 36% et 45% des tumeurs. La dose absorbée par la tumeur après RE différait significativement selon l'étendue de la nécrose histologique ( $P=0,045$ ). Les médianes de survie globale et sans progression étaient respectivement de 61,8 mois [IC 95 % : 31,4 mois-non atteint (NA)] et 49,3 mois (IC 95 % : 14 mois-NA).

### Conclusions

Des taux élevés de réponses radiologiques et histologiques ont été observés après RE chez les patients atteints de TTVP, de CHC de grande taille ou multifocaux. La chirurgie ultérieure est sûre avec des résultats dépassant de loin les attentes dans une population au pronostic autrement défavorable.

### Spécialité

Radiologie interventionnelle ; Hépatologie ; Chirurgie ; Médecine nucléaire

### Mots clés

Radiothérapie interne sélective ; carcinome hépatocellulaire (CHC) ; cancer du foie ; résection ; transplantation.